Characterization of the Metabolome of Breast Tissues from Non-Hispanic Black and Non-Hispanic White Women Reveals Correlations between Microbial Dysbiosis and Enhanced Lipid Metabolism Pathways in Triple-Negative Breast Tumors.
breast cancer
lipids
metabolome
microbiome
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Aug 2022
23 Aug 2022
Historique:
received:
10
08
2022
revised:
18
08
2022
accepted:
19
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that is non-responsive to hormonal therapies and disproportionately impact women of African ancestry. We previously showed that TN breast tumors have a distinct microbial signature that differs from less aggressive breast tumor subtypes and normal breast tissues. However, it is unknown whether these differences in breast tumor microbiota may be driven by alterations in microbial metabolites, leading to potentially protective or pathogenic consequences. The goal of this global metabolomic profiling study was to investigate alterations in microbial metabolism pathways in normal and breast tumor tissues, including TNBC, of non-Hispanic black (NHB) and non-Hispanic white (NHW) women. In this study, we profiled the microbiome (16S rRNA) from breast tumor tissues and analyzed 984 metabolites from a total of 51 NHB and NHW women. Breast tumor tissues were collected from 15 patients with TNBC, 12 patients with less aggressive luminal A-type (Luminal) breast cancer, and 24 healthy controls for comparison using UHPLC-tandem mass spectrometry. Principal component analysis and hierarchical clustering of the global metabolomic profiling data revealed separation between metabolic signatures of normal and breast tumor tissues. Random forest analysis revealed a unique biochemical signature associated with elevated lipid metabolites and lower levels of microbial-derived metabolites important in controlling inflammation and immune responses in breast tumor tissues. Significant relationships between the breast microbiome and the metabolome, particularly lipid metabolism, were observed in TNBC tissues. Further investigations to determine whether alterations in sphingolipid, phospholipid, ceramide, amino acid, and energy metabolism pathways modulate
Identifiants
pubmed: 36077608
pii: cancers14174075
doi: 10.3390/cancers14174075
pmc: PMC9454857
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Tennessee Health Science Center TN Clinical and Translational Science Institute and Methodist Mission
ID : NA
Références
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Oncotarget. 2018 Feb 7;9(14):11677-11690
pubmed: 29545929
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3748-3758
pubmed: 32015106
Front Cell Dev Biol. 2021 Sep 06;9:728759
pubmed: 34552932
World J Gastroenterol. 2016 Jan 14;22(2):557-66
pubmed: 26811607
J Biol Chem. 1994 Jul 1;269(26):17606-10
pubmed: 8021269
Semin Cell Dev Biol. 2020 Feb;98:26-33
pubmed: 31175937
J Cancer Epidemiol. 2014;2014:469251
pubmed: 24955090
Neurosci Biobehav Rev. 2020 Aug;115:15-24
pubmed: 32433924
BMC Cancer. 2022 Jan 3;22(1):30
pubmed: 34980006
Front Oncol. 2018 Aug 17;8:318
pubmed: 30175072
ACS Cent Sci. 2019 May 22;5(5):768-780
pubmed: 31139713
Breast Cancer Res. 2018 Oct 1;20(1):116
pubmed: 30285809
Oncotarget. 2016 Feb 9;7(6):6506-20
pubmed: 26646699
J Pers Med. 2021 Sep 24;11(10):
pubmed: 34683090
Sci Rep. 2019 Aug 16;9(1):11940
pubmed: 31420578
Cell Metab. 2021 Jan 5;33(1):51-64.e9
pubmed: 33181091
Cancer Biomark. 2015;15(6):783-8
pubmed: 26406420
Cell Death Dis. 2018 Feb 14;9(2):228
pubmed: 29445084
Cancer Genomics Proteomics. 2014 Nov-Dec;11(6):279-94
pubmed: 25422359
Gut Microbes. 2012 May-Jun;3(3):186-202
pubmed: 22572830
Clin Perinatol. 2014 Jun;41(2):423-35
pubmed: 24873841
Sci Rep. 2016 Aug 03;6:30751
pubmed: 27485780
FEMS Immunol Med Microbiol. 1996 Dec 1;16(2):105-15
pubmed: 8988391
Cancer Res. 2020 Mar 15;80(6):1246-1257
pubmed: 31911556
EBioMedicine. 2020 May;55:102762
pubmed: 32339939
Int J Obes (Lond). 2012 Nov;36(11):1442-9
pubmed: 22184060
BMC Cancer. 2019 May 24;19(1):495
pubmed: 31126257
Commun Biol. 2021 Oct 27;4(1):1229
pubmed: 34707244
Pediatr Infect Dis J. 1989 Jul;8(7):426-30
pubmed: 2755753
BMJ Open Gastroenterol. 2017 Jul 3;4(1):e000145
pubmed: 28944067
Int J Mol Sci. 2019 Aug 25;20(17):
pubmed: 31450675
Discov Med. 2018 May;25(139):211-223
pubmed: 29906404
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1848-55
pubmed: 22989461
Matrix Biol. 2018 Apr;67:63-74
pubmed: 29331336
Psychopharmacology (Berl). 2019 Oct;236(10):2997-3011
pubmed: 30806743
Cell Res. 2022 May;32(5):477-490
pubmed: 35105939
Oncologist. 2011;16 Suppl 1:1-11
pubmed: 21278435
Pathol Res Pract. 2017 Mar;213(3):177-182
pubmed: 28215644
Mol Oncol. 2010 Jun;4(3):209-29
pubmed: 20537966
EBioMedicine. 2020 Apr;54:102717
pubmed: 32268268
J Med Microbiol. 2004 Oct;53(Pt 10):1029-1035
pubmed: 15358827
Cancers (Basel). 2022 Jun 04;14(11):
pubmed: 35681770
Front Oncol. 2022 Jul 07;12:891619
pubmed: 35875107
Oncotarget. 2017 Aug 14;8(50):88122-88138
pubmed: 29152146
Cancer Med. 2021 Sep;10(18):6456-6467
pubmed: 34464510
J Cell Physiol. 2018 Dec;233(12):9121-9135
pubmed: 30078211
Cancer Med. 2017 Jul;6(7):1776-1786
pubmed: 28612435